# OSR Health, Inc.: overview

OSRH · OTC · CIK 1840425 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/osrh.md) · [Financials](/companies/osrh/financials.md) · [Filings](/companies/osrh/filings.md) · [Insiders](/companies/osrh/insiders.md)

Latest reported revenue: [$315.7k](/filings/0001213900-26-089904.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089904).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [823](/filings/0001213900-25-109054.md) | [915 d](/filings/0001213900-26-037395.md) | [761](/filings/0001213900-26-055492.md) | [1,136](/filings/0001213900-26-089904.md) | [628](/filings/0001213900-25-109054.md) | [381 d](/filings/0001213900-26-037395.md) | [484](/filings/0001213900-26-055492.md) | [316](/filings/0001213900-26-089904.md) |
| Gross margin | % | [21.8%](/filings/0001213900-25-109054.md) | [17.5% d](/filings/0001213900-26-037395.md) | [22.2%](/filings/0001213900-26-055492.md) | [2.9%](/filings/0001213900-26-089904.md) | [41.7%](/filings/0001213900-25-109054.md) | [34.0% d](/filings/0001213900-26-037395.md) | [33.1%](/filings/0001213900-26-055492.md) | [27.4%](/filings/0001213900-26-089904.md) |
| Operating margin | % | [(433.4%)](/filings/0001213900-25-109054.md) | [(176.2%) d](/filings/0001213900-26-037395.md) | [(383.3%)](/filings/0001213900-26-055492.md) | [(460.5%)](/filings/0001213900-26-089904.md) | [(605.9%)](/filings/0001213900-25-109054.md) | [(1674.8%) d](/filings/0001213900-26-037395.md) | [(757.6%)](/filings/0001213900-26-055492.md) | [(960.8%)](/filings/0001213900-26-089904.md) |
| Net margin | % | [(28.1%)](/filings/0001193125-24-258772.md) | [(220.9%) d](/filings/0001213900-25-034116.md) | [(1496.6%)](/filings/0001213900-26-089904.md) | [(460.2%)](/filings/0001213900-26-089904.md) | [(508.9%)](/filings/0001213900-25-109054.md) | [(1900.4%) d](/filings/0001213900-26-037395.md) | [(716.3%)](/filings/0001213900-26-089904.md) | [(318.1%)](/filings/0001213900-26-089904.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001193125-24-258772.md) | not reported | [(1.04)](/filings/0001213900-26-055492.md) | not reported | not reported | not reported | [(0.08)](/filings/0001213900-26-055492.md) | not reported |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | [3,530](/filings/0001213900-26-037395.md) | [2,906](/filings/0001213900-26-037395.md) |
| Gross margin | % | not reported | not reported | not reported | [23.0%](/filings/0001213900-26-037395.md) | [20.4%](/filings/0001213900-26-037395.md) |
| Operating margin | % | not reported | not reported | not reported | [(331.2%)](/filings/0001213900-26-037395.md) | [(631.0%)](/filings/0001213900-26-037395.md) |
| Net margin | % | not reported | not reported | not reported | [(68.3%)](/filings/0001213900-25-034116.md) | [(931.2%)](/filings/0001213900-26-037395.md) |
| Diluted EPS | $ per share | [0.00](/filings/0000898432-23-000193.md) | [(0.01)](/filings/0001193125-24-099137.md) | [0.05](/filings/0001213900-25-034116.md) | [(4.79)](/filings/0001213900-26-037395.md) | [(0.80)](/filings/0001213900-26-037395.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:ProfitLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/osrh/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $46.9k | 148,266 |  | Added +131,237 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $40.4k | 127,810 |  | New +127,810 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $40.2k | 127,195 |  | New +127,195 |
| [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $32.0k | 604,164 |  | Reduced −7,783 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $31.8k | 100,458 |  | Reduced −5,285 |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $30.1k | 95,040 |  | Unchanged |
| [Polar Asset Management Partners Inc.](/funds/1326389.md) | 2026-06-30 | $19.1k | 360,000 |  | Unchanged |
| [Periscope Capital Inc.](/funds/1695320.md) | 2026-06-30 | $15.9k | 299,900 |  | Unchanged |
| [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $15.5k | 291,824 |  | Reduced −259 |
| [TWO SIGMA SECURITIES, LLC](/funds/1450144.md) | 2026-06-30 | $14.7k | 46,537 |  | New +46,537 |

## Recent filings

[All 225 filings](/companies/osrh/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 09:17 ET | [8-K](/filings/0001213900-26-110051.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-110051 |
| 2026-10-02 | 16:32 ET | [8-K](/filings/0001213900-26-106429.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-106429 |
| 2026-08-28 | 08:00 ET | [8-K](/filings/0001213900-26-094654.md) | 8.01 Other events | 0001213900-26-094654 |
| 2026-08-25 | 11:28 ET | [8-K](/filings/0001213900-26-093379.md) | 8.01 Other events | 0001213900-26-093379 |
| 2026-08-19 | 17:05 ET | [8-K](/filings/0001213900-26-091756.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-091756 |
| 2026-08-14 | 15:08 ET | [10-Q](/filings/0001213900-26-089904.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089904 |
| 2026-08-10 | 11:09 ET | [8-K](/filings/0001213900-26-087087.md) | 5.07 Shareholder vote results | 0001213900-26-087087 |
| 2026-08-07 | 15:32 ET | [8-K](/filings/0001213900-26-086599.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-086599 |
| 2026-07-31 | 15:06 ET | [8-K](/filings/0001213900-26-083878.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-083878 |
| 2026-07-16 | 16:36 ET | [DEF 14A](/filings/0001213900-26-078706.md) | Proxy statement, period 2026-08-07 | 0001213900-26-078706 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037395.md), filed Mar 31, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/45f9f4c4-4a42-42d5-8e29-6c7132835e1b)

## About the filer

- CIK: 1840425
- Tickers: OSRH, OSRHW
- Exchange: OTC
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 09:31 ET. No prices; not investment advice.